Amicus Pharma - FOLD Quarterly EPS earnings growth

Amicus Corp - graphic logo of issuer FOLD

Amicus Therapeutics (FOLD) develops high-margin drugs for rare metabolic pathologies, easily scaling production following the completion of R&D. The quarterly EPS dynamics on GURU.Markets show that -88.90 represents the latest metric reading. Profit growth is driven by expansion into underserved orphan niches, while financial success relies on Galafold sales and the successful rollout of Pombiliti.

Amicus Therapeutics, Inc. (FOLD) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 05/09/2026

Financial and market metric breakdowns for Amicus Corp (FOLD)

- share price and consensus valuation forecast:
Stock Quotes Amicus Therapeutics, Inc.|FOLD - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Amicus Pharma|FOLD - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Amicus Therapeutics|FOLD - Company Book Value|Market Value to Book Value Ratio amicusrx.com|FOLD - Company Assets
- debt and liquidity data:
Debt to Equity Amicus Therapeutics|FOLD - Long-Term Debt to Equity|Short-Term Debt to Capital Amicus Therapeutics|FOLD - Company Total Debt Obligations|Debt to Book Capitalization Ratio Amicus Pharma|FOLD - Long-Term Debt Volume|Company Short-Term Debt Amicus Therapeutics|Quick Ratio amicusrx.com
- earnings and valuation multiples indicators:
FOLD - Net Profit|Expected Profit Amicus Therapeutics|FOLD - Price to Earnings Ratio|Forward P/E Multiple Amicus Pharma|FOLD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Amicus Pharma|FOLD - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Amicus Therapeutics|FOLD - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months amicusrx.com|FOLD - Expected net earnings per share growth this year|Expected earnings per share growth for next year Amicus Therapeutics
- sales volume and revenue information:
FOLD - Company Sales Revenue|Company Future Sales Volume Amicus Therapeutics, Inc.|FOLD - Market Cap to Sales Volume|Forward P/S Multiple Amicus Pharma
Analysis of all company metrics:Amicus Therapeutics
Manufactured product of Amicus Corp

Investors must evaluate the fundamental stability of Amicus Therapeutics (FOLD) through net income dynamics. This indicator measures the percentage change in earnings per share compared to the same quarter of the previous year. By analyzing the quarterly EPS movement, one can identify hidden margin compression or growth in efficiency. The stability of this metric confirms the success of the bioethical approach and the optimization of resources at Amicus Therapeutics (FOLD) laboratories. This demonstrates the link between ESG standards and financial returns.

Competitors of Amicus Therapeutics (FOLD)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Corp|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (metsera.com)|Year-over-year earnings per share growth for the last twelve months MoonLake MLTX|Crinetics Pharmaceuticals, Inc. (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Therapeutics Inc.|MiMedx Group Inc (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rezolute Corp (RZLT)|Year-over-year net earnings per share growth for the last 12 months Lexicon Corp LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences Inc)|Quarterly EPS earnings growth altimmune.com ALT|AARD - Year-over-year earnings per share growth for the last twelve months|Sagimet Biosciences, Inc. (SGMT) - Year-over-year net earnings per share growth for the last 12 months|BIOA: Quarterly EPS earnings growth|BMEA - Year-over-year net earnings per share change for the last twelve months|QNCX (Quince Therapeutics Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months fractyl.com (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|Quarterly EPS earnings growth agapeatpgroup.com (ATPC)|Year-over-year earnings per share growth for the last twelve months Pluri PLUR|Year-over-year net earnings per share change for the last twelve months Synlogic Inc. (SYBX)|LPCN: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months MTNB (Matinas BioPharma)|SPRB (Spruce Biosciences) - Year-over-year net earnings per share growth for the last 12 months|GLTO: Year-over-year earnings per share growth rate for the last twelve months|CTCX (Carmell Corp) - Quarterly EPS earnings growth|LUMO: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ONVO|RDUS - Earnings per share growth in annualized terms for the last twelve months